Symbols

LNTH

Lantheus Holdings·NASDAQ

--(--)

LNTH fundamentals

LNTH Q4 2025 Earnings

Lantheus Holdings (LNTH) released its earnings on Feb 26, 2026: revenue was 406.79M (YoY +4.01%), beat estimates; EPS was 1.67 (YoY +5.03%), beat estimates.

Revenue / YoY

406.79M

+4.01%

EPS / YoY

1.67

+5.03%

Report date

Feb 26, 2026

LNTH Earnings Call Summary for Q4,2025

Strategic Shift to Diagnostics: Divested SPECT business, prioritizing PET radiodiagnostics like Neuraceq (+100%+ 2026 growth) and OCTEVY (FDA March 29).
PSMA Franchise Resilience: PYLARIFY volume growth offset 8-10% net revenue decline; new PSMA PET formulation targets Q4 2026 launch with TPT reimbursement.
Financial Guidance: 2026 EPS $5-5.25, revenue $1.4-1.45B. Neuraceq and DEFINITY drive mid-term growth; R&D investment in GRPR-targeted PET.
Pipeline Optimization: PNT2003 launch planned; exploring external partnerships for non-core therapeutics.

Earnings

EPS

Revenue

Revenue & Expenses

LNTH has released its 2025 Q4 earnings report, with revenue of 406.79M, reflecting a YoY change of 4.01%, and net profit of 54.09M, showing a YoY change of 558.76%. The Sankey diagram below clearly presents LNTH's revenue sources and cost distribution.

Key Indicators

Lantheus Holdings (LNTH) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Lantheus Holdings (LNTH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Lantheus Holdings (LNTH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Lantheus Holdings (LNTH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown